Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tenofovir DF · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | 2 drug arm |
| B | ACTIVE_COMPARATOR | 3 drug arm, SOC |
| Name | Type | Description |
|---|---|---|
| Tenofovir DF | DRUG | TDF 300mg QD for 72 wks |
| lopinavir/ritonavir with 2 Nucleoside RTIs | DRUG | LPV/rSGC 400/100mg BID + 2 nucleoside RTIs as prescribed by the Investigator for 72 wks |
Inclusion Criteria: * HIV positive * \>18 years of age * HIV RNA\> 400 copies/mL * Any CD 4 cell count * Antiretroviral naïve * No acute illness Exclusion Criteria: \-
Top 20 of 28 competitors
Tenofovir DF is a small molecule drug being developed for the treatment of HIV Infection. It is currently in Phase 3 clinical development as an investigational therapy for this infectious disease indication.
Tenofovir DF is being developed by Abbott Laboratories, a company traded on the stock exchange under the ticker symbol ABT.
Tenofovir DF is currently in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities for the treatment of HIV Infection.
Tenofovir DF has one completed Phase 3 clinical trial, identified as NCT00234910. This trial evaluated the efficacy of a simplified two-drug Kaletra regimen compared to a Kaletra triple-drug standard of care regimen in treatment-naive HIV infected patients.
Tenofovir DF is not the same as Kaletra. In the clinical trial NCT00234910, Tenofovir DF was part of a regimen that included Kaletra, but they are distinct drugs used in combination for the treatment of HIV Infection.